```
     (FILE 'HOME' ENTERED AT 18:35:49 ON 10 FEB 2004)

     FILE 'REGISTRY' ENTERED AT 18:36:02 ON 10 FEB 2004
L1              STRUCTURE UPLOADED
L2           96 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 18:36:46 ON 10 FEB 2004
L3           26 S L2
L4            2 S L3 AND (WOUND? OR ULCER? OR DECUBITUS OR (PRESSURE SORE?) OR
L5         3629 S DIPYRIDAMOLE

     FILE 'REGISTRY' ENTERED AT 18:48:40 ON 10 FEB 2004
L6            1 S DIPYRIDAMOLE/CN

     FILE 'CAPLUS' ENTERED AT 18:48:53 ON 10 FEB 2004
L7         4162 S L6 OR L5
L8            0 S L7 AND L3
L9          870 S SILDENAFIL
L10          16 S L9 AND L3

     FILE 'REGISTRY' ENTERED AT 18:49:43 ON 10 FEB 2004
L11           1 S SILDENAFIL/CN

     FILE 'CAPLUS' ENTERED AT 18:49:51 ON 10 FEB 2004
L12          492 S L11
L13          889 S L12 OR L9
L14           19 S L13 AND L3
L15        20411 S TREAT? (40A) (WOUND? OR ULCER? OR DECUBITUS OR (PRESSURE SORE
L16           1 S L15 AND L14

=> save all
ENTER NAME OR (END):l09927344/l
L# LIST L1-L16 HAS BEEN SAVED AS 'L09927344/L'

=> save l14
ENTER NAME OR (END):a09927344/a
ANSWER SET L14 HAS BEEN SAVED AS 'A09927344/A'

=> save l10\
ENTER L#, L# RANGE, ALL, OR (END):end

=> save l10
ENTER NAME OR (END):b09927344/a
ANSWER SET L10 HAS BEEN SAVED AS 'B09927344/A'
```

```
     (FILE 'HOME' ENTERED AT 18:35:49 ON 10 FEB 2004)

     FILE 'REGISTRY' ENTERED AT 18:36:02 ON 10 FEB 2004
L1              STRUCTURE UPLOADED
L2           96 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 18:36:46 ON 10 FEB 2004
L3           26 S L2
L4            2 S L3 AND (WOUND? OR ULCER? OR DECUBITUS OR (PRESSURE SORE?) OR
L5         3629 S DIPYRIDAMOLE

     FILE 'REGISTRY' ENTERED AT 18:48:40 ON 10 FEB 2004
L6            1 S DIPYRIDAMOLE/CN

     FILE 'CAPLUS' ENTERED AT 18:48:53 ON 10 FEB 2004
L7         4162 S L6 OR L5
L8            0 S L7 AND L3
L9          870 S SILDENAFIL
L10          16 S L9 AND L3

     FILE 'REGISTRY' ENTERED AT 18:49:43 ON 10 FEB 2004
L11           1 S SILDENAFIL/CN

     FILE 'CAPLUS' ENTERED AT 18:49:51 ON 10 FEB 2004
L12          492 S L11
L13          889 S L12 OR L9
L14           19 S L13 AND L3
L15        20411 S TREAT? (40A) (WOUND? OR ULCER? OR DECUBITUS OR (PRESSURE SORE
L16           1 S L15 AND L14
                SAVE ALL L09927344/L
                SAVE L14  A09927344/A
                SAVE L10  B09927344/A

     FILE 'USPATFULL' ENTERED AT 19:04:26 ON 10 FEB 2004
L17          30 S L2
L18           7 S L17 AND (WOUND? OR ULCER? OR DECUBITUS OR (PRESSURE SORE?) OR

=> save l18
ENTER NAME OR (END):c09927344/a
ANSWER SET L18 HAS BEEN SAVED AS 'C09927344/A'

=>
```

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:525913 CAPLUS
DN 135:107336
ED Entered STN: 20 Jul 2001
TI Treatment of diabetic **ulcers** with pyrazolo[4,3-d]pyrimidine-7-one cGMP PDE5 inhibitors
IN Wood, Ralph E.; Davies, Michael John; Siegel, Richard Lewis
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-00
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001051042	A2	20010719	WO 2001-IB18	20010111
	WO 2001051042	A3	20020110		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1248623	A2	20021016	EP 2001-900568	20010111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003519652	T2	20030624	JP 2001-551466	20010111
	US 2003176442	A1	20030918	US 2003-169921	20030307
PRAI	GB 2000-561	A	20000111		
	WO 2001-IB18	W	20010111		

GI



I

AB This patent relates to the use of cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of diabetic **ulcers**, particularly diabetic foot **ulcers** (no data). I,

a sildenafil analog, was prepared in a multi-step sequence involving the amidation of 2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)-3-pyridinecarboxylic acid (preparation given) with 4-amino-3-ethyl-1H-pyrazole-5-carboxamide, addition of 1-bromo-2-methoxyethane to the pyrazole ring, and cyclization using potassium bis(trimethylsilyl)amide and EtOAc in EtOH. Examples of formulations are included.

ST cyclic guanosine monophosphate phosphodiesterase inhibitor prepn diabetic **ulcer** treatment; cGMP PDE5 inhibitor prepn diabetic foot **ulcer** treatment

IT 171599-83-0, Sildenafil citrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulation component; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

IT 16250-08-1P, Pyridin-2-amino-5-sulfonic acid 247582-62-3P 247582-63-4P 247582-68-9P 247582-73-6P 264920-27-6P 350047-17-5P 350047-18-6P 350047-19-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

IT 139755-83-2P, Sildenafil **334826-98-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

IT 504-29-0, 2-Aminopyridine 5308-25-8, 1-Ethylpiperazine 6482-24-2, 1-Bromo-2-methoxyethane 215298-74-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

IT **334826-98-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

RN 334826-98-1 CAPLUS

CN Piperazine, 1-[[6-ethoxy-5-[3-ethyl-4,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridinyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)



=> d hit, ibib .

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

TI **Treatment** of diabetic **ulcers** with pyrazolo[4,3-d]pyrimidine-7-one cGMP PDE5 inhibitors

AB This patent relates to the use of cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound **sildenafil**, for the **treatment** of diabetic **ulcers**, particularly diabetic foot **ulcers** (no data). I, a **sildenafil** analog, was prepared in a multi-step sequence involving the amidation of 2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)-3-pyridinecarboxylic acid (preparation given) with 4-amino-3-ethyl-1H-pyrazole-5-carboxamide, addition of 1-bromo-2-methoxyethane to the pyrazole ring, and cyclization using potassium bis(trimethylsilyl)amide and EtOAc in EtOH. Examples of formulations are included.

ST cyclic guanosine monophosphate phosphodiesterase inhibitor prepn diabetic **ulcer treatment**; cGMP PDE5 inhibitor prepn diabetic foot **ulcer treatment**

IT 171599-83-0, **Sildenafil** citrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulation component; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for **treatment** of diabetic **ulcers**)

IT 16250-08-1P, Pyridin-2-amino-5-sulfonic acid 247582-62-3P 247582-63-4P 247582-68-9P 247582-73-6P 264920-27-6P 350047-17-5P 350047-18-6P 350047-19-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for **treatment** of diabetic **ulcers**)

IT **139755-83-2P**, **Sildenafil 334826-98-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for **treatment** of diabetic **ulcers**)

IT 504-29-0, 2-Aminopyridine 5308-25-8, 1-Ethylpiperazine 6482-24-2, 1-Bromo-2-methoxyethane 215298-74-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for **treatment** of diabetic **ulcers**)

ACCESSION NUMBER: 2001:525913 CAPLUS
DOCUMENT NUMBER: 135:107336
TITLE: **Treatment** of diabetic **ulcers** with pyrazolo[4,3-d]pyrimidine-7-one cGMP PDE5 inhibitors
INVENTOR(S): Wood, Ralph E.; Davies, Michael John; Siegel, Richard Lewis
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051042	A2	20010719	WO 2001-IB18	20010111
WO 2001051042	A3	20020110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1248623	A2	20021016	EP 2001-900568		20010111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2003519652	T2	20030624	JP 2001-551466		20010111
US 2003176442	A1	20030918	US 2003-169921		20030307
PRIORITY APPLN. INFO.:			GB 2000-561	A	20000111
			WO 2001-IB18	W	20010111

=>

L18 ANSWER 6 OF 7 USPATFULL on STN

DETD . . . inflammation, leukemia, pain, epilepsy, affective disorders, dementia and geriatric confusion, obesity and gastrointestinal disorders (especially diarrhoea and irritable bowel syndrome), **wound** healing (especially diabetic and venous **ulcers** and **pressure sores**), septic shock, the modulation of gastric acid secretion, the treatment of hyperreninaemia, cystic fibrosis, restenosis, diabetic complications and athereosclerosis. In. . .

DETD . . . an in house designed applicator. Basically, pieces of tubing (ID 3 mm, OD 4 mm) 10 cm in length were **cut** and attached to a 1 ml syringes. The syringes were each filled with a control gel (containing no active ingredient). . .

IT 58-22-0, Testosterone 71-58-9, Medroxyprogesterone acetate 520-85-4, Medroxyprogesterone 521-18-6, Dihydrotestosterone 37221-79-7, Vasoactive intestinal peptide 37221-79-7D, Vasoactive intestinal peptide, analogs 139755-83-2, Sildenafil 147676-53-7 171596-29-5, IC-351 215297-27-1 224785-90-4, Vardenafil **334826-98-1** 334827-47-3 **334827-59-7** 335077-64-0 335077-70-8 389128-36-3
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

ACCESSION NUMBER: 2002:99469 USPATFULL

TITLE: Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase

INVENTOR(S): Barber, Christopher Gordon, Kent, UNITED KINGDOM
Cook, Andrew Simon, Kent, UNITED KINGDOM
Maw, Graham Nigel, Kent, UNITED KINGDOM
Pryde, David Cameron, Kent, UNITED KINGDOM
Stobie, Alan, Kent, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002052370	A1	20020502
APPLICATION INFO.:	US 2001-893585	A1	20010628 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-16684	20000706
	GB 2001-1584	20010122
	US 2000-219100P	20000718 (60)
	US 2001-274957P	20010312 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point Road, Groton, CT, 06340

NUMBER OF CLAIMS: 37

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 5141

CAS INDEXING IS AVAILABLE FOR THIS PATEN

L18 ANSWER 2 OF 7 USPATFULL on STN

SUMM . . . as burning pain, cutaneous hyperaesthesia, paraesthesias, lancinating pain, loss of pain and temperature sensation, loss of visceral pain and foot **ulceration**; ii) primarily large-fibre manifesting as loss of vibration sensation, loss of proprioception, loss of reflexes and slowed nerve conduction velocities;. . .

IT 16250-08-1P, 2-Aminopyridine-5-sulfonic acid 216394-05-7P, 3-Bromo-2-chloropyridine-5-sulfonyl chloride 247582-62-3P 247582-63-4P 247582-68-9P 247582-73-6P 254454-54-1P 264920-27-6P 334828-19-2P 334828-24-9P 334828-32-9P 334828-39-6P **334828-45-4P** 335077-39-9P 335077-45-7P 335077-51-5P 335077-57-1P 335077-59-3P 335078-01-8P 335078-02-9P 335078-18-7P
(cGMP phosphodiesterase inhibitors for the treatment of neuropathy)

IT **334826-98-1P** 334827-47-3P **334827-59-7P** 335077-64-0P 335077-70-8P
(cGMP phosphodiesterase inhibitors for the treatment of neuropathy)

ACCESSION NUMBER: 2003:232581 USPATFULL
TITLE: Treatment of neuropathy
INVENTOR(S): Grossman, Eric B., Hastings-on-Hudson, NY, UNITED STATES
Koppiker, Nandan P., Canterbury, UNITED KINGDOM
Leichter, Steven B., Cataula, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003162782	A1	20030828
APPLICATION INFO.:	US 2002-206615	A1	20020726 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-692781, filed on 19 Oct 2000, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-24958	19991021
	GB 2000-21520	20000901

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 1012
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

TI Treatment of diabetic **ulcers** with pyrazolo[4,3-d]pyrimidine-7-one cGMP PDE5 inhibitors

AB This patent relates to the use of cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of diabetic **ulcers**, particularly diabetic foot **ulcers** (no data). I, a sildenafil analog, was prepared in a multi-step sequence involving the amidation of 2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)-3-pyridinecarboxylic acid (preparation given) with 4-amino-3-ethyl-1H-pyrazole-5-carboxamide, addition of 1-bromo-2-methoxyethane to the pyrazole ring, and cyclization using potassium bis(trimethylsilyl)amide and EtOAc in EtOH. Examples of formulations are included.

ST cyclic guanosine monophosphate phosphodiesterase inhibitor prepn diabetic **ulcer** treatment; cGMP PDE5 inhibitor prepn diabetic foot **ulcer** treatment

IT 171599-83-0, Sildenafil citrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulation component; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

IT 16250-08-1P, Pyridin-2-amino-5-sulfonic acid 247582-62-3P 247582-63-4P 247582-68-9P 247582-73-6P 264920-27-6P 350047-17-5P 350047-18-6P 350047-19-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

IT 139755-83-2P, Sildenafil **334826-98-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

IT 504-29-0, 2-Aminopyridine 5308-25-8, 1-Ethylpiperazine 6482-24-2, 1-Bromo-2-methoxyethane 215298-74-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

ACCESSION NUMBER: 2001:525913 CAPLUS
DOCUMENT NUMBER: 135:107336
TITLE: Treatment of diabetic **ulcers** with pyrazolo[4,3-d]pyrimidine-7-one cGMP PDE5 inhibitors
INVENTOR(S): Wood, Ralph E.; Davies, Michael John; Siegel, Richard Lewis
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051042	A2	20010719	WO 2001-IB18	20010111
WO 2001051042	A3	20020110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,

YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1248623	A2	20021016	EP 2001-900568	20010111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519652	T2	20030624	JP 2001-551466	20010111
US 2003176442	A1	20030918	US 2003-169921	20030307

PRIORITY APPLN. INFO.: GB 2000-561 A 20000111
WO 2001-IB18 W 20010111

=>

=>
Uploading C:\Program Files\Stnexp\Queries\09927344.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 exa ful
FULL SEARCH INITIATED 15:25:09
FULL SCREEN SEARCH COMPLETED - 18 TO ITERATE

100.0% PROCESSED 18 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L2 1 SEA EXA FUL L1

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 334826-98-1 REGISTRY
CN Piperazine, 1-[[6-ethoxy-5-[3-ethyl-4,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridinyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-(Methoxyethyl)-5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
CN 5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
FS 3D CONCORD
MF C23 H33 N7 O5 S

CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19 REFERENCES IN FILE CA (1907 TO DATE)
19 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus

=> d 1-2 hit, ibib

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

IT Foot
(diabetic foot **ulcer**; kit for reducing aching caused by phosphodiesterase V inhibitors)

IT **Ulcer**
(diabetic **ulcers**; kit for reducing aching caused by phosphodiesterase V inhibitors)

IT 139755-83-2, Sildenafil 147676-53-7 171596-29-5, Tadalafil 215297-27-1 224785-90-4, Vardenafil 247580-98-9 **334826-98-1** 335077-70-8
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(kit for reducing aching caused by phosphodiesterase V inhibitors)

ACCESSION NUMBER: 2003:450774 CAPLUS
DOCUMENT NUMBER: 139:17600
TITLE: Kit for reducing aching caused by phosphodiesterase V (PDE5) inhibitors
INVENTOR(S): Abel, Samantha; Ellis, Peter
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1317924	A1	20030611	EP 2002-258123	20021126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
WO 2003047588	A1	20030612	WO 2002-IB4933	20021122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2003192614	A2	20030709	JP 2002-349628	20021202
US 2003124150	A1	20030703	US 2002-310608	20021205

PRIORITY APPLN. INFO.: GB 2001-29274 A 20011206
US 2002-355286P P 20020208

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l5 sss ful
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 15:32:59
FULL SCREEN SEARCH COMPLETED - 390 TO ITERATE

100.0% PROCESSED 390 ITERATIONS 96 ANSWERS
SEARCH TIME: 00.00.01

L6 96 SEA SSS FUL L5

L7 26 L6